Experienced in Prostate Cancer

Dr. Dustin E. Stevenson

Hematology Oncology | Hematology | Oncology
1325 E Church St Ste 301, 
Santa Maria, CA 
Experienced in Prostate Cancer
1325 E Church St Ste 301, 
Santa Maria, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dustin Stevenson is a Hematologist Oncology specialist and a Hematologist in Santa Maria, California. Dr. Stevenson is rated as an Experienced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Essential Thrombocythemia, Breast Cancer, Colorectal Cancer, and Deep Vein Thrombosis.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Prostate Cancer.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1325 E Church St Ste 301, Santa Maria, CA 93454

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
View 8 Less Clinical Trials
Similar Doctors
Advanced in Prostate Cancer
Dr. Thomas B. Woliver
Hematology Oncology | Hematology | Oncology
Advanced in Prostate Cancer
Dr. Thomas B. Woliver
Hematology Oncology | Hematology | Oncology
540 West Pueblo Street, 
Santa Barbara, CA 
 (45.7 miles away)
805-563-5800
Languages Spoken:
English
See accepted insurances

Thomas Woliver is a Hematologist Oncology specialist and a Hematologist in Santa Barbara, California. Dr. Woliver is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, and Familial Prostate Cancer.

Advanced in Prostate Cancer
Dr. Daniel R. Lewis
Hematology Oncology | Hematology | Oncology
Advanced in Prostate Cancer
Dr. Daniel R. Lewis
Hematology Oncology | Hematology | Oncology

Pacific Central Coast Health Centers

715 Tank Farm Rd, Suite C, 
San Luis Obispo, CA 
 (31.2 miles away)
805-543-5577
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Lewis is a Hematologist Oncology specialist and a Hematologist in San Luis Obispo, California. Dr. Lewis is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Angiosarcoma, and Childhood Iron Deficiency Anemia.

Advanced in Prostate Cancer
Dr. Erick W. Hjortsvang
Hematology | Oncology
Advanced in Prostate Cancer
Dr. Erick W. Hjortsvang
Hematology | Oncology

Pcr Oncology Inc

Arroyo Grande, CA 
 (21.4 miles away)
805-474-9143
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Erick Hjortsvang is a Hematologist and an Oncologist in Arroyo Grande, California. Dr. Hjortsvang is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Essential Thrombocythemia, Chronic Lymphocytic Leukemia (CLL), Familial Colorectal Cancer, and Colorectal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stevenson's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 120 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile